Sharp Edge Labs, Inc., http://www.sharpedgelabs.com a drug discovery biology firm, and Creagen Biosciences Inc. http://www.creageninc.com a medicinal chemistry firm, today announced that they have entered into a compound library screening agreement to test Creagen’s medicinal chemistry compound libraries in Sharp Edge Labs’ biological screening assays. The agreement covers all libraries in the Creagen collection and will be applied to Sharp Edge Labs screening assays across therapeutic areas, including, Parkinson’s, Alzheimer’s, Cancer, Cystic Fibrosis and Lysosomal Storage Disorders.
Scott Sneddon, PhD, J.D., President and CEO of Sharp Edge Labs noted that this was a unique opportunity to bring Creagen’s compounds into Sharp Edge Labs’ trafficking assays, and to probe previously unexploited miolecular mechanisms for these diseases. The agreement is open-ended, with additional compounds being made available and additional screening assays being offered by agreement of the companies. “We’re excited to test Creagen’s compounds across a portfolio of first-in-class cellular trafficking assays using our technology’” Sneddon said. “These assays probe novel biology, and expose molecular targets not previously exploited in drug discovery programs.” Sneddon said. Prior to co-founding Sharp Edge Labs, Sneddon was part of the Drug Discovery program at Genzyme Corp., where he oversaw numerous similar compound library screening collaborations.
